insights_auto
Why is ALMKT down 4.57%?
Dive Deeperchevron_right
ALMKT:EPA
Mauna Kea Technologies SA
€0.10
arrow_downward
-4.57%(-0.0048) 1D
Oct 23, 12:30:47 PM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALMKT...
Open
€0.10
High
€0.10
Low
€0.10
Mkt. cap
19.46M
Avg. vol.
426.16K
Volume
291.18K
P/E ratio
0.85
52-wk high
€0.23
52-wk low
€0.07
EPS
€0.12
Shares outstanding
195.26M
No. of employees
56
Open
€0.10
High
€0.10
Low
€0.10
Mkt. cap
19.46M
Avg. vol.
426.16K
Volume
291.18K
P/E ratio
0.85
52-wk high
€0.23
52-wk low
€0.07
EPS
€0.12
Shares outstanding
195.26M
No. of employees
56
News stories
From web sources and news partners
Reuters
·
57 minutes ago
Mapping the Market: Path to S&P 500 rally strewn with obstacles
BigGo Finance
·
1 hour ago
S&P 500 Falls 1.2% but 335 Constituents Close Higher as U.S. Stocks Split Into AI and Non-AI Markets
The Motley Fool
·
49 minutes ago
Investors Just Got Bad News From the Federal Reserve. Here's What History Says Comes Next.
Profile
Mauna Kea Technologies is a global medical device company focused on endomicroscopy, the field of microscopic imaging during endoscopy procedures. The company researches, develops and markets tools to visualize, detect, and rule out abnormalities including malignant and pre-malignant tumors or lesions in the gastrointestinal and pulmonary tracts.
The company makes Cellvizio, a probe-based Confocal Laser Endomicroscopy system, which provides physicians and researchers with real-time access to histological information during standard endoscopy procedures through high-resolution cellular imaging of internal tissues.
Cellvizio is used in medical applications such as gastrointestinal endoscopy, pulmonology and urology to help physicians diagnose lesions and make accurate treatment decisions in real-time.
Cellvizio went public in July 2011 and trades on the Euronext Paris exchange. Wikipedia
About Mauna Kea Technologies SA